Medical use of cannabis for glaucoma

(October 2018)

Background

The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.

Access Details

Read the full policy statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS).

Related Resources

Recommendations from the Canadian Neuro-Ophthalmology Society regarding Neuro-Ophthalmology Care During the COVID-19 Pandemic

May 29, 2020 As we transition into a new normal...

More Info

COS – Ophthalmic Surgery Prioritization

Ophthalmic Surgery Prioritization Updated, May 28, 2020 Hospitals and ambulatory...

More Info

Checklist on Reopening Ophthalmology Clinics during COVID-19

Checklist on Reopening Ophthalmology Clinics during COVID-19 May 15, 2020...

More Info

Please join us tomorrow Thursday May 28th at 7pm EST for the final webinar in our series - A Path to a New Vision: What Now? Optimizing Our New Normal #stayathome4CPD #COVID19 #eyehealth ow.ly/fTAC50zRsb4

Last week from Can Ophthal Society's Twitter via Hootsuite Inc.

Can Ophthal Society's Twitter via Twitter Web Client